Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Progression 68% Improvement Relative Risk Time to viral- 32% no CI c19hcq.org Agusti et al. HCQ for COVID-19 EARLY TREATMENT Is early treatment with HCQ beneficial for COVID-19? Prospective study of 142 patients in Spain Lower progression with HCQ (not stat. sig., p=0.21) Agusti et al., Enfermedades Infecciosas y Microb.., doi:10.1016/j.eimc.2020.10.023 Favors HCQ Favors control
Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: prospective, non-randomized trial
Agusti et al., Enfermedades Infecciosas y Microbiología Clínica, doi:10.1016/j.eimc.2020.10.023
Agusti et al., Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection:.., Enfermedades Infecciosas y Microbiología Clínica, doi:10.1016/j.eimc.2020.10.023
Dec 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small trial of low dose HCQ for healthcare workers with mild SARS-CoV-2 showing 68% lower progression to pneumonia, p = 0.21, and faster, but not statistically significant viral clearance. There were no ICU admissions or deaths. Prospective non-randomized study. The figures and supplementary data are not currently available in the pre-proof edition.
risk of progression, 68.4% lower, RR 0.32, p = 0.21, treatment 2 of 87 (2.3%), control 4 of 55 (7.3%), NNT 20, pneumonia.
time to viral-, 31.8% lower, relative time 0.68, treatment 87, control 55.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Agusti et al., 9 Dec 2020, prospective, Spain, peer-reviewed, median age 37.0, 13 authors, average treatment delay 5.0 days, dosage 400mg bid day 1, 200mg bid days 2-5.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: G Model EIMC-2342; No. of Pages 7 ARTICLE IN PRESS Enferm Infecc Microbiol Clin. 2020;xxx(xx):xxx–xxx www.elsevier.es/eimc Original Article Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial Antonia Agusti a,b , Elena Guillen a,b , Alfonso Ayora c , Andres Anton d,e , Cristina Aguilera a,b , Xavier Vidal a,b , Cristina Andres d,e , Manuel Alonso c , Meritxell Espuga c , Juliana Esperalba d,e , Ma Queralt Gorgas b,f , Benito Almirante g,h , Esteban Ribera g,h,∗ a Clinical Pharmacology Service, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Barcelona, Spain Departament de Farmacologia, Terapèutica I Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain c Occupational Health Service, Vall d’Hebron Hospital Universitari, Barcelona, Spain d Respiratory Viruses Unit, Microbiology Department, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Barcelona, Spain e Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, Bellaterra, Spain f Clinical Pharmacy Service, Vall d’Hebron Hospital Universitari, Barcelona, Spain g Infectious Diseases Department, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Hospital Universitari, Barcelona, Spain h Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain b a r t i c l e i n f o Article history: Received 1 September 2020 Accepted 29 October 2020 Available online xxx Keywords: SARS-CoV-2 infection COVID-19 Hydroxychloroquine Healthcare workers Outpatients a b s t r a c t Objectives: To assess the efficacy and safety of hydroxychloroquine (HCQ) compared with no treatment in healthcare workers with mild SARS-CoV-2 infection. Methods: Prospective, non-randomized study. All health professionals with confirmed COVID-19 between April 7 and May 6, 2020, non-requiring initial hospitalization were asked to participate. Patients who accepted treatment were given HCQ for five days (loading dose of 400 mg q12 h the first day followed by200 mg q12 h). Control group included patients with contraindications for HCQ or who rejected treatment. Study outcomes were negative conversion and viral dynamics of SARS-CoV-2, symptoms duration and disease progression. Result: Overall, 142 patients were enrolled: 87 in treatment group and 55 in control group. The median age was 37 years and 75% were female, with few comorbidities. There were no significant differences in time to negative conversion of PCR between both groups. The only significant difference in the probability of negative conversion of PCR was observed at day 21 (18.7%, 95%CI 2.0–35.4). The decrease of SARS-CoV2 viral load during follow-up was similar in both groups. A non significant reduction in duration of some symptoms in HCQ group was observed. Two patients with HCQ and 4 without treatment developed pneumonia. No patients required admission to the Intensive Care Unit or died. About 50% of patients presented mild side effects of HCQ, mainly diarrhea. Conclusions: Our study failed to show a substantial benefit of HCQ in viral dynamics and in resolution of clinical symptoms in health care workers with mild COVID-19. © 2020 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Enfermedades Infecciosas y Microbiologı́a Clı́nica. Eficacia y seguridad de hidroxicloroquina en profesionales sanitarios con infección leve por SARS-CoV-2: Estudio..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit